Lupin stock climbs nearly 4% on launch of Mirabegron Extended-Release tablets in US

Mirabegron Extended-Release tablets had estimated annual sales of $1,019 million in the US

Related Keywords

Mumbai ,Maharashtra ,India ,United States ,South Africa ,America ,Asia Pacific ,Lupin Ltd ,Astellas Pharma Global Development Inc ,Drug Administration ,Mirabegron Extended Release ,Myrbetriq Extended Release ,Astellas Pharma Global Development ,Active Pharmaceutical Ingredients ,Latin America ,Lupin ,Lupin Share Price ,Upin Stock Price ,Mirabegron Extended Release Tablets ,S Fda ,